NCT05814952View on ClinicalTrials.gov

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2028

Conditions
X-linked Retinoschisis
Interventions
GENETIC

LX103 Injection

Qualified subjects will receive a single unilateral intravitreal injection of LX103 at Day 0 in the trial.

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai

Sponsors
All Listed Sponsors
collaborator

Innostellar Biotherapeutics

UNKNOWN

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER